Bayer
NEWS
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
As usual, it was a busy week for clinical trial updates. Here’s a look.
The results of the Phase III VICTORIA trial set up the potential for the companies to seek regulatory approval for vericiguat.
The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
Bayer Plc launches LifeHub UK as part of a global network of Bayer global innovation hubs. LifeHub UK is designed to accelerate and optimise disease detection and data-driven drug discovery by developing Artificial Intelligence (AI)-enabled imaging solutions.
Expands on existing collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using clinical AI
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
JOBS
IN THE PRESS